With FDA rejection, Amag loses out on broader use of anemia drug Feraheme

The FDA dashed Amag Pharmaceuticals' hopes for its anemia drug Feraheme. The agency rejected Amag's application for broader use of the treatment for iron deficiency, citing a lack of evidence of its safety. The drug is approved to treat anemia in patients with chronic kidney disease, but Amag wanted to market it to a much broader group of anemia patients. Release | Report